ReviewCancer journal (Sudbury, Mass.)
PD-1/PD-L1 Axis in Lung Cancer.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Pathogenic mechanisms and resistance profiles of microbial pulmonary infections in lung cancer: a systematic review.BMC infectious diseases · 2025Pooled it
- Pooled it
- Trial
- From Mechanisms to Therapeutic Innovation in Non-Small Cell Lung Cancer: A Knowledge-Depth Translational Mapping with Experimental Validation.International journal of molecular sciences · 2026Article
- Obstructive sleep apnea as a modifier of endocrine toxicities associated with immune checkpoint inhibitors in lung cancer.Frontiers in immunology · 2026Review
- Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC.Frontiers in immunology · 2026Article
- Role of signaling pathways in lung cancer development and advances in targeted therapies (Review).Oncology letters · 2025Review
- Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies.Cancers · 2025Review
- Comparative performance of PD-L1 scoring by pathologists and AI algorithms.Histopathology · 2025Article
- Structure-activity relationship ofEJNMMI radiopharmacy and chemistry · 2025Article
- A single-centre, randomised trial to compare diagnostic yield and safety between endobronchial cryobiopsy and endobronchial forceps biopsy procedure in patients with endobronchial lesions.Lung India : official organ of Indian Chest Society · 2025Article
- Harnessing TAGAP to improve immunotherapy for lung squamous carcinoma treatment by targeting c-Rel in CD4+ T cells.Cancer immunology, immunotherapy : CII · 2025Article
- Infective Complications of Endobronchial Ultrasound-Transbronchial Needle Aspiration (EBUS-TBNA) and Clinical Biomarkers: A Concise Review.Diagnostics (Basel, Switzerland) · 2025Review
- The potential impact of GLS and PDHA1 on tumor immunity and immunotherapy response in LUSC.Frontiers in genetics · 2025Article
- Review
- Multi‑omics identification of a signature based on malignant cell-associated ligand-receptor genes for lung adenocarcinoma.BMC cancer · 2024Article
- Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands.EJNMMI radiopharmacy and chemistry · 2024Article
- Enhancing safety and therapeutic efficacy: PD-1 inhibitor and recombinant human endostatin combination in advanced non-small cell lung cancer patients.American journal of translational research · 2024Article
- Recent advances in molecular targeted therapy of lung cancer: Possible application in translation medicine.Iranian journal of basic medical sciences · 2024Review
- Emerging Immunotherapy Approaches for Treating Prostate Cancer.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cancer immunotherapies have revolutionized the treatment of non-small cell lung cancer. Yet, only a small subset of patients will benefit from PD-1 or PD-L1 blockade. PD-L1 tumor cell expression is the only approved biomarker at present. Tumor mutational burden and other emerging biomarkers should improve patient selection. Combination therapy approaches with chemotherapy or cytotoxic T-lymphocyte-associated protein 4 blockade may increase the proportion of patients who benefit from immunotherapy. Although use of immunotherapy in lung cancers with targetable oncogenes has not been particularly successful, the benefit of PD-(L)1 inhibitors in early-stage disease is emerging. This review briefly describes the evolution of the clinical development and future directions of PD-(L)1 blockade in patients with lung cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.